18:19 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Merck reports Phase II data for Keytruda in breast cancer

Merck & Co. Inc. (NYSE:MRK) reported data from 40 evaluable patients with trastuzumab-resistant, HER2- and PD-L1-positive metastatic breast cancer in the Phase II portion of the Phase Ib/II KEYNOTE-014 (PANACEA) trial showing that 200 mg...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

MammaPrint: Phase III data

Agendia N.V. , Amsterdam, the Netherlands   Product: MammaPrint   Business: Diagnostic   Molecular target: Not applicable   Description: Breast cancer prognostic test using a 70-gene signature chip   Indication: Predict the risk of metastases...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Clinical News

Ibrance palbociclib: Phase III started

Pfizer began the open-label, international Phase III PALLAS trial to compare 125 mg oral Ibrance once daily for the first 21 days of each 28-day cycle for 2 years plus standard endocrine adjuvant therapy for...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

Herceptin trastuzumab: Phase III data

The open-label, international Phase III ALTTO trial in 8,381 patients with HER2-positive early breast cancer showed that adjuvant treatment with oral Tykerb lapatinib plus IV Herceptin trastuzumab missed the primary endpoint of improving DFS vs....
07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

Tykerb: Phase III data

The open-label, international Phase III ALTTO trial in 8,381 patients with HER2-positive early breast cancer showed that adjuvant treatment with oral Tykerb lapatinib plus IV Herceptin trastuzumab missed the primary endpoint of improving DFS vs....
02:04 , Jun 3, 2014 |  BC Extra  |  Clinical News

Adjuvant Tykerb, Herceptin miss in Phase III ALTTO trial

Adjuvant treatment of HER2-positive early breast cancer with oral Tykerb lapatinib from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) plus IV Herceptin trastuzumab from Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit missed the primary endpoint of improving...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Company News

Myriad Genetics, Tesaro deal

Tesaro will use Myriad's BRACAnalysis test to select patients likely to respond to the Tesaro's niraparib for enrollment in two Phase III trials of the poly(ADP-ribose) polymerase (PARP) inhibitor. Myriad markets BRACAnalysis to assess a...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Tesaro, Breast International Group (BIG), European Network of Gynecological Oncological Trial Groups (ENGOT), European Organization for Research and Treatment o

Tesaro partnered with the three not-for-profits to conduct two separate Phase III cancer trials of niraparib . Under its deal with BIG and EORTC, the partners will conduct a trial of niraparib in breast cancer...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Clinical News

Herceptin trastuzumab: Final Phase III data

Roche said that in April the HERA trial reached the target number of 725 DFS events needed for 80% power to detect a true hazard ratio of 0.8 to compare the 1- and 2-year treatment...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

MammaPrint: Completed Phase III enrollment

Agendia and the European Organization for Research and Treatment of Cancer (EORTC) and Breast International Group (BIG) completed enrollment of >6,600 patients in the open-label, international Phase III MINDACT trial comparing MammaPrint vs. common clinical...